Posted by Michael Wonder on 02 Apr 2026
AbbVie's Epkinly gets health insurance coverage for DLBCL in Korea
1 April 2026 - AbbVie Korea said Wednesday that its bispecific antibody Epkinly (epcoritamab), will receive national health insurance coverage starting in April for the third-line or later treatment of relapsed or refractory diffuse large B-cell lymphoma.
The coverage targets adult patients with relapsed or refractory diffuse large B-cell lymphoma, who have undergone two or more lines of systemic therapy. The reimbursement is applicable only to patients who have not previously received a CD3 and CD20 bispecific antibody treatment.
